
Considering the use of animal models in drug development
Professor Andy Whiting, CEO of Nevrargenics, asks whether animal models should be used as the default regulatory requirement and explores the times to use them. Animal models (AMs) have generally been seen as useful for drug development and biomedical research for many years. They are assumed to closely mimic human… Read More















